Új kezelési lehetoség a 2-es típusú diabetes terápiájában: DPP-4-gátlók (sitagliptin)

Translated title of the contribution: A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)

Tatjána Ábel, János Fehér

Research output: Contribution to journalShort survey

9 Citations (Scopus)

Abstract

Type 2 diabetes is a very common worldvide disorder. A good glycemic controll is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.

Translated title of the contributionA new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)
Original languageHungarian
Pages (from-to)1012-1016
Number of pages5
JournalOrvosi hetilap
Volume151
Issue number25
DOIs
Publication statusPublished - Jun 1 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)'. Together they form a unique fingerprint.

  • Cite this